Monte Rosa Therapeutics Inc.
NASDAQ · GLUE·Cambridge, MA·Small-cap·Phase 1
Pioneering molecular glue degraders using its proprietary QuEEN platform to selectively degrade disease-relevant proteins. Three clinical programs span inflammation/cardiovascular disease (MRT-8102, NEK7) and oncology (MRT-2359, GSPT1), plus a partnered VAV1 program with Novartis worth up to $2.1B in milestones.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Monte Rosa Therapeutics JP Morgan 2026 | JPM Healthcare | January 1, 2026 | 11 |